ライフサイエンスコーパス: plasma level

1 n physiologically relevant functional C1-INH plasma levels.

2 2854746) were analyzed for associations with plasma levels.

3 red a strong correlation between FX and PTX2 plasma levels.

4 001), T3t/T4t (P = .001), and TSH (p = .001) plasma levels.

5 th halogen substitutions displayed sustained plasma levels after oral dosing in rodents leading to ef

6 idence of associations between mother's PFAS plasma levels and ADHD [per natural log nanograms per mi

7 e correlated with increased VEGF and FGF2 BM plasma levels and BM microvascular density.

8 We determined day profiles of histamine plasma levels and DAO serum activities in 33 patients wi

9 tients with MCT12 mutation exhibited reduced plasma levels and increased fractional excretion of guan

10 betes; however, they often increase glucagon plasma levels and induce the proliferation of glucagon-s

11 FGF21 treatment increased adiponectin plasma levels and normalized insulin sensitivity in Bscl

12 used to detect interactions between hormonal plasma levels and ocular parameters.

13 Adherence was assessed by drug plasma levels and patient self-report.

14 genic rat model with high endogenous ghrelin plasma levels and, interestingly, improved glucose toler

15 Interestingly, their respective plasma levels are interdependent.

16 odulatory properties, was tested because its plasma levels are lowered in obesity.

17 Moreover, soluble IL-27 plasma levels are negatively associated with the breadth

18 ypeptide 1 (CYP7B1) and results in increased plasma levels, as well as fecal excretion, of bile acids

19 metabolites of mitochondrial oxidation whose plasma levels associate with metabolic diseases.

20 Stable F9 plasma levels at 7-20% of normal were obtained, and trea

21 L shedding from T cells and increased sCD62L plasma levels at CML diagnosis on molecular response to

22 Despite the lower high-density lipoprotein plasma levels, both transgenic strains responded to LPS

23 d stress-induced increases in corticosterone plasma levels, but did not significantly alter HPA-axis

24 CF patients showed increased FGF23 plasma levels, but KL levels were not different.

25 costerone at a dose that maintained elevated plasma levels characteristic of STZ-DM.

26 gh-fat diet resulted in a decreased IL-1beta plasma level compared with vehicle-treated mice (5.2+/-1

27 In drug-induced acute liver failure, plasma levels correlate with outcome.

28 retic peptide (NP) and B-type NP, with their plasma levels correlating with severity of ischemia.

29 e is confirmed in a larger D/R cohort, IL-10 plasma levels could be used to guide the length of proph

30 tricted protein intake ammonia and glutamine plasma levels decreased with subsequent improvement of t

31 ients and unaffected carriers showed that FH plasma levels determined by the nonmutated chromosome mo

32 ardiomyocyte hypertrophy, elevated NT-proBNP plasma levels, fluid and protein loss in pulmonary inter

33 entrations also exhibited rapid increases in plasma levels following consumption of breakfasts supple

34 ted human dose required to achieve sustained plasma levels >/=10 times the hADAMTS-5 IC50 is 5 mg q.d

35 macokinetic properties sufficient to sustain plasma levels >50 times its IDE IC50 value, studies in r

36 Concomitant high vancomycin trough plasma levels had been observed in each patient.

37 FF) were correlated at both the gene and the plasma levels, implicating IFN induction as a factor in

38 ual fat pads and the decrease in adiponectin plasma levels in 12- vs. 4-week-old animals.

39 we demonstrate that macrophages regulate FX plasma levels in an SR-AI-dependent manner.

40 oach to identify three proteins with altered plasma levels in asthmatic children, representing one of

41 Finally, we confirmed low 25D plasma levels in patients with IBD with active inflammat

42 to be due to a gradual decrease in sorafenib plasma levels in patients.

43 The 10-fold lower DMXB-A plasma levels in smokers suggest that chronic smoking en

44 variant had significantly elevated TGF-beta1 plasma levels (median, 23 376.49 vs 18 476.52 pg/mL; P =

45 e estimated hazard ratios (HRs) for death by plasma level of 25(OH)D (insufficient, < 20 ng/mL; relat

46 Mean prediagnostic plasma level of 25(OH)D was 24.6 ng/mL, and 165 patients

47 Plasma level of amyloid-beta42 measured at several time

48 uced pulmonary inflammation and elevation of plasma level of interferon-beta and -gamma and interleuk

49 with participants in the lowest quartile for plasma level of MIC1, the multivariate hazard ratio for

50 elevated anti-MICA sensitization and reduced plasma level of soluble MICA in recipients, 2 potential

51 Increased plasma level of soluble urokinase-type plasminogen activ

52 The plasma level of TLR-4 was found to be increased from 0.9

53 with variable viral loads and measuring the plasma levels of >600 soluble proteins, our data highlig

54 y subjects using colon delivery capsules and plasma levels of (13) C-SCFAs (13) C-glucose, (13) C-cho

55 tyl)benzoic acid, 12, provided 5-fold higher plasma levels of 1 compared to oral administration of 1

56 s the only prodrug that achieved substantial plasma levels of 1.

57 Plasma levels of 17 cytokines were screened in the same

58 type 1 (HIV-1) coinfection, we measured the plasma levels of 22 cytokines and chemokines in Zambian

59 etabolism and the potential utility of using plasma levels of 24S-OHC as a biomarker of brain cholest

60 atic cancer who had sufficient prediagnostic plasma levels of 25(OH)D.

61 nd 0.5 mg/kg, respectively, corresponding to plasma levels of 270.8 and 9.2 ng/mL, respectively.

62 Plasma levels of 3-chlorotyrosine, 3-nitrotyrosine, and

63 Using an affinity proteomics approach, plasma levels of 362 proteins covered by antibodies from

64 rols had no significant differences in their plasma levels of 38 inflammatory cytokines/chemokines me

65 2.5 years) with suspected coronary disease, plasma levels of 53 previously reported biomarkers of ca

66 Plasma levels of 8-hydroxy-2'-deoxyguanosine and 8-isopr

67 We analyzed plasma levels of Abeta42 and Abeta40 in a cohort of 719

68 Plasma levels of Abeta42 and Abeta40 were reduced in AD

69 In summary, our study identified low plasma levels of acylcarnitines in patients with VTE and

70 We investigated whether increasing plasma levels of adiponectin (APN), a pleiotropic adipok

71 Cyclo-oxygenase-2(-/-) mice had increased plasma levels of ADMA and monomethyl-l-arginine and redu

72 Agxt2 expression and activity, and elevated plasma levels of ADMA, SDMA and BAIB, compared to wild-t

73 Plasma levels of all coagulation factors and of the main

74 We measured plasma levels of alpha-granule-derived factors in the li

75 lome profiling showed significant changes in plasma levels of amino acids, biogenic amines, acylcarni

76 We measured plasma levels of angiopoietin-1 and angiopoietin-2 at st

77 t, the chemoreflex stimulation increases the plasma levels of anti-inflammatory cytokine interleukin

78 or genetic deletion of Tnfrsf14, diminishes plasma levels of antigen-specific IgG1 and IgE antibodie

79 ApoC-III inhibition by volanesorsen reduced plasma levels of apoC-II, apoC-III, triacylglycerols, an

80 Low plasma levels of apoE are associated with increased risk

81 However, it remains unclear whether plasma levels of apoE confer additional risk.

82 High plasma levels of apolipoprotein A-I (apoA-I) correlate w

83 (BAC) transgene were generated, resulting in plasma levels of approximately 300 ng/ml human PCSK9.

84 The plasma levels of arginase I, ornithine decarboxylase (OD

85 Plasma levels of arginine, citrulline, ornithine, asymme

86 Inhibition of VLDL secretion reduces plasma levels of atherogenic apolipoprotein B (apoB) lip

87 Plasma levels of autotaxin and its enzymatic product, ly

88 We evaluated plasma levels of autotaxin, interleukin 6 (IL-6), solubl

89 Transplantation trial, we determined whether plasma levels of B-type natriuretic peptide (BNP) and ca

90 Plasma levels of B-type natriuretic peptide, hs-TnI (hig

91 We also determined plasma levels of BAFF and expression of BAFF receptors o

92 epression Scale, adjusted P=0.01), and lower plasma levels of biomarkers of vascular inflammation (os

93 ients with type 1 diabetes present increased plasma levels of both HA and HYAL1.

94 nts with poor glycemic control, although the plasma levels of both proteins were similar among all pl

95 Although plasma levels of C-reactive protein (CRP) have been show

96 Elevated preoperative and postoperative plasma levels of C-reactive protein were associated with

97 Plasma levels of C5, C5a, and terminal complement comple

98 Admission plasma levels of catecholamines (adrenaline, noradrenali

99 days in humans or 14 days in mice) increases plasma levels of cell-free hemoglobin and heme.

100 Plasma levels of chem163S in FXI-deficient patients were

101 Plasma levels of chemokines (monocyte chemotactic protei

102 Interestingly, plasma levels of chemokines CC chemokine ligand 5 and CX

103 f lanadelumab was assessed by measurement of plasma levels of cleaved high-molecular-weight kininogen

104 Twenty-one days of CUS decreased basal plasma levels of corticosterone and produced a shorter l

105 During the first week of life the elevated plasma levels of CRP predicted the risk of BPD (OR 3.4,

106 r had a manual occupation, through increased plasma levels of CSF3 (G-CSF; beta = 0.29; P = 0.002), a

107 therapies also have differential effects on plasma levels of CXCL10, soluble IL-2R, and IL-1alpha.

108 Plasma levels of CXCL13 in HIV-1-infected antiretroviral

109 unique inflammatory profile, including high plasma levels of CXCL13, sCD40L, IP10, RANTES, and TNFal

110 In relapsing MS patients, plasma levels of CXCL5, another ELR(+) CXC chemokine, we

111 We determined the plasma levels of CysC and NGAL in 429 patients hospitali

112 also occur in parallel with Elmo1, as do the plasma levels of cystatin C, lipid peroxides, and TGFbet

113 Plasma levels of cytokeratin-18 fragments are reliable n

114 Secondary endpoints included alveolar and plasma levels of cytokines and soluble form of the recep

115 nistration of D-serine with 11h enhanced the plasma levels of D-serine in mice compared to the oral a

116 In 102 kidney recipients, we measured plasma levels of dd-cfDNA and correlated the levels with

117 t for drug-resistant epilepsy that increases plasma levels of decanoic acid and ketones.

118 Also, appreciable plasma levels of DHE were seen within 5min for both deli

119 t with full metabolomics data (n = 709), low plasma levels of DMG were significantly associated with

120 the association of genetic variants with the plasma levels of each of the 156 Framingham Cardiovascul

121 owth factor (PlGF) correlated with increased plasma levels of endothelin-1 (ET-1), a potent vasoconst

122 Diazoxide resulted in a 37% increase in plasma levels of epinephrine and a 44% increase in plasm

123 At the same consultations blood plasma levels of estradiol (E2) and thyroid hormones (TS

124 Additionally, plasma levels of exosomal neural-derived IRS-1 phosphory

125 y with the demonstration that an increase in plasma levels of FABP4 is inhibited by chloroquine treat

126 In conclusion, plasma levels of Fgf21 reflect liver fat accumulation an

127 In a subcohort (n=131) we also measured plasma levels of FGF23, calcium, phosphate, parathyroid

128 Plasma levels of fitusiran increased in a dose-dependent

129 is a highly regulated process that maintains plasma levels of free fatty acids to supply energy to ce

130 While elevated plasma levels of FXI have been associated with venous th

131 We measured plasma levels of G0 (low risk), G1, and G2 APOL1 in 3450

132 ral nutrition was also associated with lower plasma levels of gamma-glutamyltransferase and alkaline

133 Maximum plasma levels of GEN were dose-dependent and ranged betw

134 lin receptor antagonist D-Lys GHRP-6 reduced plasma levels of GLP-1 and insulin and diminished oral g

135 Injection of control mice with GIP increased plasma levels of GLP1, insulin, and glucose tolerance; t

136 We sought to determine whether plasma levels of glycogen phosphorylase BB (GPBB) isofor

137 -cell activation, dendritic cell counts, and plasma levels of gut mucosal dysfunction markers intesti

138 sm and immune activation but did not improve plasma levels of gut mucosal dysfunction markers.

139 t important in the periodic table with blood plasma levels of H(+), Na(+) and Ca(2+) being indicators

140 Plasma levels of HBV DNA were quantified by PCR reaction

141 ty of PPARdelta agonist GW501516 to increase plasma levels of HDL-cholesterol.

142 Plasma levels of hemin and hpx (at admission, day 3, and

143 Plasma levels of hemopexin, which were decreased in wome

144 Plasma levels of heparin-binding protein, procalcitonin,

145 Plasma levels of high-sensitivity C-reactive protein (hs

146 recordings, coronary angiography, and serial plasma levels of high-sensitivity troponin T and midregi

147 Plasma levels of histamine, leukotriene B4, prostaglandi

148 s with homocystinuria have markedly elevated plasma levels of homocysteine and methionine and reduced

149 r use was not associated with changes in the plasma levels of host biomarkers indicative of activatio

150 cant associations between VTE occurrence and plasma levels of human immunodeficiency virus type I enh

151 Notably, plasma levels of IFN-gamma, a key pathogenic cytokine in

152 ed a case-control study that measured serial plasma levels of IFN-gamma-inducible protein 10 (IP-10),

153 prospectively evaluated associations between plasma levels of IGF-1 and IGFBP-3 and laparoscopically

154 ficiency impaired CR-mediated changes in the plasma levels of IGF-1 and insulin.

155 nts correlated with parasitemia, whereas the plasma levels of IL-17A, IL-17F, and IL-6 were less para

156 The plasma levels of IL-17A, MCP-1, and monokine induced by

157 After CLP, NLRP3(-/-) mice showed reduced plasma levels of IL-1beta and IL-6.

158 , Tnfa, and Crp expression in WBCs, elevated plasma levels of IL-1beta, IL-6, and IL-8, increased IL-

159 Here, we found that plasma levels of IL-22 and its upstream cytokine, IL-23,

160 no statistical difference between groups in plasma levels of IL-35 (P >0.05).

161 gingival crevicular fluid (GCF), saliva, and plasma levels of IL-35 in periodontal disease and health

162 e unaltered by 11beta-HSD1 deficiency though plasma levels of IL-4, IL-6 and TNF-alpha were slightly

163 body that targets IL-1beta, markedly reduces plasma levels of IL-6, hsCRP, and fibrinogen with little

164 Plasma levels of IL-8 correlated significantly with IFCC

165 Elevated plasma levels of IL-8 potentially contribute to the cros

166 s with diabetes and periodontitis had higher plasma levels of IL-8 than patients with periodontitis a

167 easuring changes in immune cell frequencies, plasma levels of immune mediators, and differentially ex

168 sponse to lipopolysaccharide attenuating the plasma levels of inflammatory cytokines such as tumor ne

169 Plasma levels of inflammatory markers (neopterin, kynure

170 Plasma levels of insulin and glucose were compared using

171 of oxidant/inflammatory genes, and increased plasma levels of intercellular cell adhesion molecule-1

172 Plasma levels of interferon-gamma-inducible protein 10 (

173 pro-inflammatory markers, including elevated plasma levels of interleukin-1beta (IL-1beta).

174 lower levels of tryptase in sputum and lower plasma levels of interleukin-5.

175 Plasma levels of interleukin-6 were significantly reduce

176 e searched for human genetic determinants of plasma levels of intestinal fatty acid-binding protein (

177 Higher plasma levels of IP-10 (P = .0011), TNF-RII (P = .0002),

178 g peripheral artery tonometry (EndoPAT), and plasma levels of l-arginine, arginase-1, and asymmetric

179 of these metabolites strongly correlate with plasma levels of lactate and amino acid, as shown by inc

180 roots when fed a regular diet and at normal plasma levels of LDL.

181 LA-DR+CD8+ (activated) T-cell frequency, and plasma levels of lipopolysaccharide (LPS), LPS binding p

182 on, BPTES nanoparticles had no effect on the plasma levels of liver enzymes in contrast to CB-839, a

183 is a rare disease characterized by elevated plasma levels of low-density lipoprotein cholesterol (LD

184 oides stercoralis infection, we measured the plasma levels of LPS and other microbial translocation m

185 y 49 after anti-CMV therapy, (iii) increased plasma levels of markers of inflammation (pentraxin 3 an

186 nd diapedesis, which corresponded with lower plasma levels of matrix metalloproteinase-8 and soluble

187 In the setting of HF, elevated plasma levels of MBG are associated with right ventricul

188 Plasma levels of MDSC mediators S100A8/A9, S100A12, and

189 transaminase activities and, more recently, plasma levels of metabolites involved in PLP-dependent r

190 tal tumor samples from 2 large studies, high plasma levels of MIC1 (growth differentiation factor 15)

191 INF individuals exhibit significantly higher plasma levels of microbial translocation markers (LPS, s

192 HBeAg-positive patients had higher plasma levels of miR-122-5p, miR-125b-5p, miR-192-5p, mi

193 Pretreatment plasma levels of miR-301a-3p and miR-145-5p were higher

194 In CAV patients, plasma levels of miR-628-5p and miR-155 were significant

195 Patients with plasma levels of mitochondrial DNA in the highest quarti

196 -specific T-cell responses and directly with plasma levels of molecules involved in Wnt/beta-catenin

197 c NE, beta-AR, and downregulation of TAT and plasma levels of NE.

198 Patients with severe AP had increased plasma levels of NET components compared with controls.

199 ncussed football players would have elevated plasma levels of neurotoxic kynurenine metabolites and r

200 ant activity in vivo manifested by decreased plasma levels of neutrophil secretory proteins and signi

201 Thus, increased plasma levels of neutrophil secretory proteins, includin

202 in CsA-treated patients by changing GCF and plasma levels of OSMs.

203 cy on platelets and strongly correlated with plasma levels of P-selectin, platelet factor 4, and plat

204 he Stellarex DCB in comparison with PTA, and plasma levels of paclitaxel fall to low levels within 1

205 d systemic inflammation, including increased plasma levels of pentraxin-2 and activated antigen-prese

206 To compare the circulating plasma levels of peptide YY and ghrelin in control subje

207 The plasma levels of peptide YY did not differ between patie

208 Plasma levels of peptides and hormones related to cardio

209 romoted statistically significant changes in plasma levels of phosphatidylcholines, sphingomyelins an

210 clot density (CD) (by confocal microscopy), plasma levels of plasminogen activator inhibitor (PAI-1)

211 Plasma levels of PPi and the degree of ectopic mineraliz

212 its and platelet reactivity index, and PK by plasma levels of prasugrel's active metabolite.

213 Increased fasting plasma levels of pro-NT (a stable NT precursor fragment

214 ting endothelial progenitor cells (EPCs) and plasma levels of proangiogenic vascular endothelial grow

215 We assessed plasma levels of progesterone, prolactin, and lipids and

216 n and puncture-induced sepsis, decreases the plasma levels of proinflammatory cytokines and organ inj

217 Urinary and plasma levels of protein S, sTyro3, sAxl, and sMer were

218 utrition in the Netherlands (EPIC-NL) study, plasma levels of protein-bound Nepsilon-(carboxymethyl)l

219 Plasma levels of PTF1+2 may be useful for assessment of

220 Plasma levels of reduced (cysteine and glutathione) and

221 Plasma levels of resistin, a proinflammatory cytokine an

222 of Evans blue dye from the brain, increased plasma levels of S100B, an astrocytic protein, and down-

223 e, suggesting that it is caused by decreased plasma levels of S1P and reduced S1P1 stimulation.

224 We analyzed whether plasma levels of sCD40L and sCD40R predict changes in re

225 We measured plasma levels of selected miRNAs in subjects with predia

226 transdermal selegiline suggesting that when plasma levels of selegiline are elevated, brain MAO-A mi

227 inal pain, fatigue, muscle weakness, and low plasma levels of selenium.

228 whether the high-dose treatment used lowered plasma levels of small uremic solutes other than urea.

229 Plasma levels of soluble factors associated with inflamm

230 d regression model analysis demonstrate that plasma levels of soluble interleukin-27 (IL-27) are sign

231 Stenosis application increased plasma levels of soluble P-selectin in wild-type but not

232 Aberrant plasma levels of sphingolipids contribute to metabolic d

233 regulating Wnt signaling and that decreased plasma levels of sVLDLR-N may contribute to Wnt signalin

234 Further, plasma levels of sVLDLR-N were reduced in both type 1 an

235 cells in RIC mice and elevated blood and BM plasma levels of T helper1 cytokines.

236 Plasma levels of taurine, lathosterol, bile acids (tauro

237 CsA use significantly alters GCF and plasma levels of TGM-2 and OSMs.

238 GCF and plasma levels of TGM-2 were analyzed by enzyme-linked im

239 Plasma levels of Th17- and Treg-related cytokines includ

240 Comparably, plasma levels of the ADAM17 substrate syndecan-1 were si

241 of the trial was to assess whether extending plasma levels of the alpha7-nicotinic acetylcholine rece

242 1 analog therapies maintain chronically high plasma levels of the analog and can lead to loss of spat

243 e clearest effects of insulin were to reduce plasma levels of the branched chain amino acids (BCAs) l

244 ion study to test the hypothesis that raised plasma levels of the branched-chain amino acids isoleuci

245 We previously reported that elevated plasma levels of the immune-modulator IL-10 are associat

246 Plasma levels of the inflammatory biomarker high-sensiti

247 Plasma levels of the inflammatory cytokine tumor necrosi

248 resistance, this is associated with elevated plasma levels of the insulin-sensitising, adipose-derive

249 so was associated with a marked reduction in plasma levels of the main proinflammatory cytokines and

250 ted in a significant synergistic increase in plasma levels of the neutrophil chemoattractant macropha

251 Elevated plasma levels of the osteocyte-derived hormone fibroblas

252 combination of studies we now show EPO uses plasma levels of the pseudohalide thiocyanate (SCN(-)) a

253 The plasma levels of these metabolites strongly correlate wi

254 the effects of CpG DNA on bleeding time and plasma levels of thrombin-antithrombin complexes and tis

255 Plasma levels of ticagrelor and its active metabolite AR

256 Mean pre- and post-dose plasma levels of ticagrelor were 35% and 38% lower, resp

257 We conclude that plasma levels of TIM3, sTNFR1, ST2, and IL6 are informat

258 incident CHD was positively associated with plasma levels of titanium and arsenic, and inversely ass

259 irectly transported, the Oat3KO had elevated plasma levels of TMAO, which is associated with cardiova

260 Plasma levels of total cholesterol (T-CHL), low density

261 Surprisingly, arglabin also reduced plasma levels of total cholesterol and triglycerides to

262 intake, enhanced body fat mass, and elevated plasma levels of triglycerides and cholesterol.

263 study, we observed a significant increase of plasma levels of TRX80 in old subjects compared with hea

264 y day 360 in abstinent AH patients; however, plasma levels of tumor necrosis factor alpha, IL-8, IL-1

265 Mean plasma levels of tumor necrosis factor alpha, interferon

266 but reduced neutrophil accumulation and the plasma levels of tumor necrosis factor-alpha and granulo

267 Cases had higher plasma levels of uncarboxylated MGP (ucMGP) and carboxyl

268 However, low plasma levels of vascular endothelial growth factor (VEG

269 ttacks per year were characterized by higher plasma levels of VEGF-A, VEGF-C, and Ang2 compared with

270 Despite elevated plasma levels of VEGFA in fs120 tumor-bearing mice and a

271 In addition, the identification of increased plasma levels of VEGFs and Angs in patients with C1-INH-

272 No changes in plasma levels of very low-density lipoprotein/low-densit

273 We identify reduced plasma levels of von Willebrand factor (VWF) and reduced

274 Basal plasma levels of von Willebrand factor and recruitment o

275 Although plasma levels of VWF and PDGFB correlated modestly (rho

276 After activation of plasma, levels of the most potent form of chemerin, chem

277 ent with therapeutically relevant isradipine plasma levels, or Cav1.3 LTCC deficiency in 6-OHDA-treat

278 and CFHR2 were down-regulated with decreased plasma levels (p < 0.01).

279 E2 plasma levels (p = .092) and time period of measurement

280 elationship between HIV-1 viremia and CXCL13 plasma levels, PBMCs from uninfected donors were stimula

281 e cell number and basal and stimulated GLP-1 plasma levels potentiating the glucose-stimulated insuli

282 performance, while disease severity and drug plasma level predicted the change in fronto-striatal eff

283 endothelial (HMEC-1) cell assay, reduced FH plasma levels produced by the nonmutated chromosome corr

284 d zeaxanthin dietary supplementation despite plasma levels showing continuous exposure to lutein and

285 This was associated with higher CXCL13 plasma levels suggesting increased homing of TFH to seco

286 y a central role in maintaining high albumin plasma levels through a cellular recycling pathway.

287 ive, population-based study and relate their plasma levels to risk of CVD.

288 ary excretion of cotinine despite comparable plasma levels was observed in Hhip (+/-) heterozygotes;

289 Changes of hormone plasma levels were correlated with changes in regional S

290 s were carried out on hairless rats, and DHE plasma levels were determined by liquid chromatography-t

291 TRX1 and TRX80 plasma levels were determined with a specific ELISA.

292 erimental findings, baseline myeloperoxidase plasma levels were independently associated with a histo

293 d transforming growth factor beta (TGF-beta) plasma levels were measured in 22 pediatric patients wit

294 Plasma levels were obtained 2.5 h post administration.

295 Day 7 IVM plasma levels were positively associated with body mass

296 tration-time profiles, time at which maximum plasma levels were reached and the estimated bioavailabi

297 Lowering cholesterol plasma levels with ezetimibe in apoE(-/-) mice reversed

298 study suggests a novel association of PDGFB plasma levels with VTE.

299 Monitoring IL-10 plasma levels within 1 month prophylaxis suspension appe

300 o anesthetized dogs for 7 hours, maintaining plasma levels within the therapeutic range.